http://www.novonordisk.com/press/se...307-9f67-19c1ed903d5f&sShowLanguageCode=en-GB
In type 2 patients, a significantly lower rate of overall hypoglycaemic events was seen in the insulin degludec group, compared to those taking insulin glargine (11.1 vs. 13.6 episodes/patient-year)1; in type 1 diabetes this figure was comparable between the two treatment arms. The rate of hypoglycaemia at night* was 25% lower in both type 1 and type 2 diabetes for patients treated with insulin degludec, compared to those taking insulin glargine (4.4 vs. 5.9 episodes/patient-year and 1.4 vs. 1.8 episodes/patient-year respectively).1,2
In type 2 patients, a significantly lower rate of overall hypoglycaemic events was seen in the insulin degludec group, compared to those taking insulin glargine (11.1 vs. 13.6 episodes/patient-year)1; in type 1 diabetes this figure was comparable between the two treatment arms. The rate of hypoglycaemia at night* was 25% lower in both type 1 and type 2 diabetes for patients treated with insulin degludec, compared to those taking insulin glargine (4.4 vs. 5.9 episodes/patient-year and 1.4 vs. 1.8 episodes/patient-year respectively).1,2
